Edwin B Walker

Summary

Affiliation: Providence Health System
Country: USA

Publications

  1. pmc Exhaustive expansion: A novel technique for analyzing complex data generated by higher-order polychromatic flow cytometry experiments
    Janet C Siebert
    CytoAnalytics, Denver, CO, USA
    J Transl Med 8:106. 2010
  2. pmc The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer
    Tobias Hahn
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213, USA
    BMC Cancer 11:471. 2011
  3. ncbi request reprint gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells
    Edwin B Walker
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Cancer Res 10:668-80. 2004
  4. pmc Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization
    Edwin B Walker
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Cancer Res 14:5270-83. 2008
  5. doi request reprint Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood
    Edwin B Walker
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Cancer Res 15:2541-51. 2009
  6. pmc CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice
    Li Xin Wang
    Laboratory of Cancer Immunobiology, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
    Eur J Immunol 40:1375-85. 2010
  7. ncbi request reprint Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses
    John W Smith
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, 4805 NE Glisan St, 5F40, Portland, OR 97213 2967, USA
    J Clin Oncol 21:1562-73. 2003
  8. pmc Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts
    Christian H Poehlein
    Laboratory of Molecular and Tumor Immunology, Earle A Chiles Research Institute, Robert W Franz Cancer Center, Providence Portland Medical Center, Portland, OR 97213, USA
    Eur J Immunol 39:3121-33. 2009
  9. pmc Signaling through OX40 enhances antitumor immunity
    Shawn M Jensen
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR 97213, USA
    Semin Oncol 37:524-32. 2010
  10. pmc Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity
    Ulf Petrausch
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center and Providence Portland Medical Center, Portland, OR 97213, USA
    J Immunol 183:3682-9. 2009

Collaborators

Detail Information

Publications15

  1. pmc Exhaustive expansion: A novel technique for analyzing complex data generated by higher-order polychromatic flow cytometry experiments
    Janet C Siebert
    CytoAnalytics, Denver, CO, USA
    J Transl Med 8:106. 2010
    ....
  2. pmc The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer
    Tobias Hahn
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213, USA
    BMC Cancer 11:471. 2011
    ....
  3. ncbi request reprint gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells
    Edwin B Walker
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Cancer Res 10:668-80. 2004
    ..The data further support the combined use of tetramer binding and functional assays in correlated ex vivo and IVS settings as a standard for immunomonitoring of cancer vaccine patients...
  4. pmc Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization
    Edwin B Walker
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Cancer Res 14:5270-83. 2008
    ..We sought to characterize the phenotype and function of gp100 peptide-specific memory CD8+ T cells in melanoma patients after primary gp100(209-2M) immunization and assess the anamnestic response to boosting immunization...
  5. doi request reprint Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood
    Edwin B Walker
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon 97213, USA
    Clin Cancer Res 15:2541-51. 2009
    ..The aim of this study was to characterize the primary gp100(209-2M)-specific T-cell response in vaccine-draining, metastases-free lymph nodes and peripheral blood of peptide-vaccinated stage I to III melanoma patients...
  6. pmc CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice
    Li Xin Wang
    Laboratory of Cancer Immunobiology, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
    Eur J Immunol 40:1375-85. 2010
    ..Our results demonstrate the lymphopenia-driven proliferation of CD122+CD8+ Treg in reconstituted lymphodepleted mice limited the antitumor efficacy of DC vaccination in conjunction with adoptive transfer of tumor-specific T cells...
  7. ncbi request reprint Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses
    John W Smith
    Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Providence Portland Medical Center, 4805 NE Glisan St, 5F40, Portland, OR 97213 2967, USA
    J Clin Oncol 21:1562-73. 2003
    ..To measure the CD8+ T-cell response to a melanoma peptide vaccine and to compare an every-2-weeks with an every-3-weeks vaccination schedule...
  8. pmc Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts
    Christian H Poehlein
    Laboratory of Molecular and Tumor Immunology, Earle A Chiles Research Institute, Robert W Franz Cancer Center, Providence Portland Medical Center, Portland, OR 97213, USA
    Eur J Immunol 39:3121-33. 2009
    ....
  9. pmc Signaling through OX40 enhances antitumor immunity
    Shawn M Jensen
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR 97213, USA
    Semin Oncol 37:524-32. 2010
    ..Combining strategies that prime tumor-specific T cells together with OX40 signaling could generate and maintain a therapeutic antitumor immune response...
  10. pmc Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity
    Ulf Petrausch
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center and Providence Portland Medical Center, Portland, OR 97213, USA
    J Immunol 183:3682-9. 2009
    ....
  11. ncbi request reprint Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein
    Dominik Ruttinger
    Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, OR 97213, USA
    J Immunother 31:43-51. 2008
    ....
  12. pmc Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects
    Ulf Petrausch
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, 4805 NE Glisan Street, Portland, OR 97213, USA
    Curr Mol Med 9:673-82. 2009
    ..Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings...
  13. ncbi request reprint Monitoring cytokine profiles during immunotherapy
    Janet C Siebert
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Cancer Center, Portland, OR 97213, USA
    Immunotherapy 2:799-816. 2010
    ..We present strategies for analyzing data, emphasizing both multidimensional analysis and the value of treating each donor as his or her own control...
  14. doi request reprint Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG
    Todd A Triplett
    Robert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA
    Eur J Immunol 42:1893-905. 2012
    ....
  15. ncbi request reprint Monitoring immune responses in cancer patients receiving tumor vaccines
    Edwin B Walker
    Providence Portland Medical Center, Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Portland, Oregon 97213, USA
    Int Rev Immunol 22:283-319. 2003
    ..The sensitivity and utility of the assays and present arguments advocating their integrated use in future immunomonitoring studies are also discussed...